Psoriasiform exfoliative erythroderma induced by golimumab
Male
03 medical and health sciences
0302 clinical medicine
Tumor Necrosis Factor-alpha
Antibodies, Monoclonal
Humans
Middle Aged
Dermatitis, Exfoliative
3. Good health
DOI:
10.1111/ced.12402
Publication Date:
2014-08-22T15:35:40Z
AUTHORS (5)
ABSTRACT
Golimumab is a fully human anti-tumour necrosis factor (TNF)-α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti-TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (10)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....